Reference · Navigation
What to screen, and when.
A curated index across the markers Healicus references, organised by age band and by topic. Each line points into the underlying marker entry, where the test, the guideline targets, and the citations live in full.
By age
Your 20s
Baseline everything. Numbers in this decade are reference points you'll measure against for the next fifty years.
- →
ApoB
Lab markerApoB is recommended for risk assessment, particularly in people with high triglycerides, diabetes, obesity or very low LDL-C.
ESC/EAS 2019 dyslipidaemia · +2 more
- →
hsCRP
Lab markerOptional addition to global risk assessment in intermediate-risk adults; repeat fasting if elevated to rule out transient cause.
AHA/CDC 2003 · +1 more
- →
HbA1c
Lab markerRisk assessment from age 40, or from 25 in people of South Asian, Chinese, African-Caribbean or Black African family background; a blood test (HbA1c or fasting glucose) if the risk score is high.
NICE PH38
- →
Vitamin D (25-OH)
Lab markerRoutine testing not recommended in healthy adults, including those with darker skin or obesity; testing remains appropriate in conditions such as malabsorption or osteoporosis.
Endocrine Society 2024 · +1 more
- →
Ferritin
Lab markerTest in adults with unexplained fatigue, reduced exercise capacity, restless legs, hair loss, or menstrual blood loss.
BSH 2021 · +1 more
- →
Lipoprotein(a)
Lab markerMeasure at least once in every adult's lifetime; reasonable in young adulthood. Repeat testing usually not needed.
ESC 2019 dyslipidaemia · +1 more
- →
Homocysteine
Lab markerSometimes measured once as part of an extended cardiovascular workup; repeated if B12/folate are being corrected.
Expert review (Spence 2007), no screening guideline
- →
Fasting insulin
Lab markerNo guideline recommends routine fasting-insulin testing; assays are not standardised. A doctor may consider it alongside glucose tests when insulin resistance is suspected.
No screening guideline
- →
HOMA-IR
Lab markerUseful when investigating early insulin resistance; less helpful once diabetes is established.
Common practice
- →
Omega-3 Index
Lab markerUseful once to establish baseline; repeat 3–6 months after starting or stopping omega-3 supplementation.
Common practice
- →
eGFR
Lab markerAnnual creatinine + eGFR for adults with diabetes, hypertension, or known CKD.
KDIGO 2024 · +1 more
- →
Cystatin C
Lab markerUse cystatin C when creatinine-based eGFR is suspected to misclassify (extreme body composition, or borderline result).
KDIGO 2024
- →
TSH
Lab markerNo routine screening; test when symptoms or risk factors are present.
ATA 2014 · +1 more
- →
Free T4
Lab markerTest alongside TSH when TSH is abnormal, or when central thyroid disease is suspected.
ATA 2014
- →
Testosterone (total)
Lab markerMeasure in men with consistent symptoms (low libido, fatigue, depressed mood, reduced muscle mass). Repeat for confirmation before treating.
Endocrine Society 2018 (men) · +1 more
- →
ALT
Lab markerEvaluate persistently elevated ALT regardless of magnitude; investigate metabolic, alcohol, viral, and drug causes.
AASLD 2017 (Kwo) · +1 more
- →
GGT
Lab markerHelpful when characterising hepatobiliary patterns alongside ALT, AST, ALP. Routine isolated screening not recommended.
AASLD 2017 (Kwo)
- →
Albumin
Lab markerReviewed at any routine blood draw. Trend over years carries more signal than any single value.
Standard panel inclusion
- →
PSA
Lab markerShared decision-making from age 50; from 45 with elevated risk (family history, African American men).
ACS 2024
- →
Vitamin B12
Lab markerTest in adults with unexplained anaemia, macrocytosis, neurological symptoms, glossitis, or risk factors (vegan/vegetarian diet, metformin or PPI use, autoimmune conditions, prior gastrointestinal surgery).
BCSH 2014 (Devalia) · +1 more
- →
Folate
Lab markerMeasure alongside B12 when investigating macrocytic anaemia, unexplained symptoms, or pre-pregnancy planning.
BCSH 2014
- →
Iron studies
Lab markerOrder alongside ferritin when symptoms suggest iron deficiency despite normal ferritin, or when ferritin is elevated and overload is being considered.
BSH 2021
- →
Haemoglobin & CBC
Lab markerReviewed at any routine blood draw. Trend matters more than single-point values.
Standard panel inclusion
- →
uACR
Lab markerAnnual for adults with diabetes, hypertension, cardiovascular disease, or family history of CKD.
KDIGO 2024 · +1 more
- →
IGF-1
Lab markerIndicated when GH excess (acromegaly) or deficiency is suspected. Routine population screening of healthy adults not recommended.
Endocrine Society 2011 (adult GH deficiency)
- →
Morning cortisol
Lab markerMorning serum cortisol is a first-line screen for adrenal insufficiency (low) or, via dexamethasone suppression, Cushing's (high), ordered for suspected disease, not routine longevity screening.
Endocrine Society 2016 · +1 more
- →
RBC magnesium
Lab markerNo body recommends population magnesium screening. Testing is reserved for symptoms, malabsorption, diuretic or PPI use, or refractory hypokalaemia/hypocalcaemia.
No screening guideline
- →
Zinc (RBC)
Lab markerNo routine population screening; assess in suspected deficiency (poor intake, malabsorption, high demand), interpreting any single biomarker alongside diet and clinical picture.
BOND zinc review 2016
- →
Faecal calprotectin
Lab markerRecommended to help distinguish IBD from IBS in adults with lower-GI symptoms where cancer is not suspected, to avoid unnecessary endoscopy.
NICE DG11 · +1 more
- →
DEXA scan
ImagingRisk-stratified screening from age 50, earlier if specific risk factors (steroid use, premature menopause, prior fragility fracture).
NOGG 2021 (UK)
- →
Coronary CT calcium score
ImagingAfter a score of zero, MESA data suggest a repeat scan is worth considering after about 3–7 years depending on age, sex and risk profile, sooner with diabetes.
MESA (Dzaye 2021)
- →
Colonoscopy
Imaging10-year interval after a high-quality normal colonoscopy in average-risk adults.
ESGE 2020
- →
Low-dose CT (lung)
ImagingSame eligibility plus consideration for additional risk factors (occupational exposure, family history).
NCCN 2024
- →
AAA ultrasound
ImagingOne-time ultrasound for men in the year they turn 65.
NHS AAA Screening Programme · +1 more
- →
Dermatological skin check
ImagingInsufficient evidence for routine population screening of asymptomatic adults.
USPSTF 2023 · +1 more
- →
Home sleep apnea test
ImagingAppropriate confirmatory study for uncomplicated suspected moderate-severe OSA. Not suitable for cases with significant comorbidity, suspected central apnea, or pediatric.
AASM 2017
- →
Polysomnography
ImagingIndicated when HSAT is inconclusive, when comorbidities or atypical presentations exist, for suspected central apnea, periodic limb movement disorder, parasomnias, or pediatric assessment.
AASM 2017
- →
Carotid intima-media thickness
ImagingRoutine CIMT measurement is not recommended for cardiovascular risk assessment in a first assessment (Class III). The earlier 2010 ACCF/AHA guideline had rated it Class IIa.
ACC/AHA 2013 · +2 more
- →
Grip strength
Functional testCentile charts cover ages 4 to 90, so a mid-life baseline can be compared with age- and sex-matched norms; no guideline sets a testing interval below age 60.
Normative data (Dodds 2014)
- →
6-minute walk test
Functional testStandardised protocol for clinical and research use. Periodic monitoring useful when tracking rehabilitation progress.
ATS / ERS 2014
- →
Comprehensive stool microbiome
Functional testNot recommended for routine clinical use or self-diagnosis. If used at all, treat as an exploratory snapshot; composition changes with diet within days.
Microbiome research literature
- →
Heart rate variability (HRV)
Wearable metricIn athlete studies, daily morning readings summarised as 7-day rolling averages are used; single values are noisy.
Athlete monitoring studies (Plews 2014) · +1 more
- →
VO₂max
Wearable metricCardiorespiratory fitness should be considered a clinical vital sign; reasonable to assess (by estimation or formal test) at routine preventive visits.
AHA 2016 · +1 more
- →
Resting heart rate
Wearable metricTrack as a daily/weekly metric; trends matter more than single readings.
AHA 2016
- →
Sleep efficiency
Wearable metricTrack over weekly rolling averages; identify patterns rather than fixating on single nights.
Common practice
- →
Blood pressure
Wearable metricAnnual screening for adults 40+; every 3–5 years for adults 18–39 at low risk. Home or ambulatory confirmation before diagnosing hypertension.
USPSTF 2021 · +3 more
- →
Waist circumference
Wearable metricUseful at any age; track monthly when working on body composition, otherwise annually.
WHO 2008 · +1 more
- →
Sleep regularity index
Wearable metricRead as a rolling weekly trend, not a single night; the value of regularity is in sustained consistency.
Sleep-health framing
- →
Sleep-onset latency
Wearable metricTrack latency alongside other symptoms over at least 2 weeks; insomnia is a clinical pattern over time, not one bad night.
European insomnia guideline 2023
- →
STOP-Bang
QuestionnaireQuestionnaires and prediction tools should not be used to diagnose OSA without a sleep study. Adults with symptoms or risk factors (habitual snoring, witnessed apnoeas, daytime sleepiness, obesity, treatment-resistant hypertension, atrial fibrillation) should have a comprehensive sleep evaluation.
AASM 2017 · +2 more
- →
Epworth Sleepiness Scale
QuestionnaireQuestionnaires such as the ESS can support a clinical assessment but should not be used to diagnose OSA without a sleep study.
AASM 2017
- →
PHQ-9
QuestionnaireRecommends screening for depression in all adults; instruments like PHQ-9 are the standard tool.
USPSTF 2023
- →
GAD-7
QuestionnaireRecommends screening for anxiety disorders in all adults aged 19–64.
USPSTF 2023
- →
MoCA
QuestionnaireEvidence is insufficient to assess screening for cognitive impairment in older adults without symptoms; tools like the MoCA are used when a patient, family member or clinician raises a concern.
USPSTF 2020
- →
PSQI
QuestionnaireUsed in clinical sleep evaluation and to track response to treatment such as CBT-I over weeks.
Common research / clinical practice
- →
AUDIT-C
QuestionnaireRecommends screening for unhealthy alcohol use in adults aged 18+ with brief intervention for those at risk. AUDIT-C is the most-used screening instrument.
USPSTF 2018
- →
UCLA Loneliness Scale (Version 3)
QuestionnaireUseful as a baseline and periodic re-measure during major life transitions (retirement, bereavement, relocation).
Common research / clinical practice
- →
Sleep apnea workup
Screening workflowQuestionnaires such as STOP-Bang and ESS should not be used to diagnose OSA without a sleep study. HSAT is acceptable for uncomplicated suspected moderate-to-severe OSA; PSG for ambiguous or comorbid cases.
AASM 2017 · +1 more
Your 30s
Trends start to matter. Cardiometabolic markers begin drifting in directions that compound.
- →
ApoB
Lab markerApoB is recommended for risk assessment, particularly in people with high triglycerides, diabetes, obesity or very low LDL-C.
ESC/EAS 2019 dyslipidaemia · +2 more
- →
hsCRP
Lab markerOptional addition to global risk assessment in intermediate-risk adults; repeat fasting if elevated to rule out transient cause.
AHA/CDC 2003 · +1 more
- →
HbA1c
Lab markerRisk assessment from age 40, or from 25 in people of South Asian, Chinese, African-Caribbean or Black African family background; a blood test (HbA1c or fasting glucose) if the risk score is high.
NICE PH38
- →
Vitamin D (25-OH)
Lab markerRoutine testing not recommended in healthy adults, including those with darker skin or obesity; testing remains appropriate in conditions such as malabsorption or osteoporosis.
Endocrine Society 2024 · +1 more
- →
Ferritin
Lab markerTest in adults with unexplained fatigue, reduced exercise capacity, restless legs, hair loss, or menstrual blood loss.
BSH 2021 · +1 more
- →
Lipoprotein(a)
Lab markerMeasure at least once in every adult's lifetime; reasonable in young adulthood. Repeat testing usually not needed.
ESC 2019 dyslipidaemia · +1 more
- →
Homocysteine
Lab markerSometimes measured once as part of an extended cardiovascular workup; repeated if B12/folate are being corrected.
Expert review (Spence 2007), no screening guideline
- →
Fasting insulin
Lab markerNo guideline recommends routine fasting-insulin testing; assays are not standardised. A doctor may consider it alongside glucose tests when insulin resistance is suspected.
No screening guideline
- →
HOMA-IR
Lab markerUseful when investigating early insulin resistance; less helpful once diabetes is established.
Common practice
- →
Omega-3 Index
Lab markerUseful once to establish baseline; repeat 3–6 months after starting or stopping omega-3 supplementation.
Common practice
- →
eGFR
Lab markerAnnual creatinine + eGFR for adults with diabetes, hypertension, or known CKD.
KDIGO 2024 · +1 more
- →
Cystatin C
Lab markerUse cystatin C when creatinine-based eGFR is suspected to misclassify (extreme body composition, or borderline result).
KDIGO 2024
- →
TSH
Lab markerNo routine screening; test when symptoms or risk factors are present.
ATA 2014 · +1 more
- →
Free T4
Lab markerTest alongside TSH when TSH is abnormal, or when central thyroid disease is suspected.
ATA 2014
- →
Testosterone (total)
Lab markerMeasure in men with consistent symptoms (low libido, fatigue, depressed mood, reduced muscle mass). Repeat for confirmation before treating.
Endocrine Society 2018 (men) · +1 more
- →
ALT
Lab markerEvaluate persistently elevated ALT regardless of magnitude; investigate metabolic, alcohol, viral, and drug causes.
AASLD 2017 (Kwo) · +1 more
- →
GGT
Lab markerHelpful when characterising hepatobiliary patterns alongside ALT, AST, ALP. Routine isolated screening not recommended.
AASLD 2017 (Kwo)
- →
Albumin
Lab markerReviewed at any routine blood draw. Trend over years carries more signal than any single value.
Standard panel inclusion
- →
PSA
Lab markerShared decision-making from age 50; from 45 with elevated risk (family history, African American men).
ACS 2024
- →
Vitamin B12
Lab markerTest in adults with unexplained anaemia, macrocytosis, neurological symptoms, glossitis, or risk factors (vegan/vegetarian diet, metformin or PPI use, autoimmune conditions, prior gastrointestinal surgery).
BCSH 2014 (Devalia) · +1 more
- →
Folate
Lab markerMeasure alongside B12 when investigating macrocytic anaemia, unexplained symptoms, or pre-pregnancy planning.
BCSH 2014
- →
Iron studies
Lab markerOrder alongside ferritin when symptoms suggest iron deficiency despite normal ferritin, or when ferritin is elevated and overload is being considered.
BSH 2021
- →
Haemoglobin & CBC
Lab markerReviewed at any routine blood draw. Trend matters more than single-point values.
Standard panel inclusion
- →
uACR
Lab markerAnnual for adults with diabetes, hypertension, cardiovascular disease, or family history of CKD.
KDIGO 2024 · +1 more
- →
IGF-1
Lab markerIndicated when GH excess (acromegaly) or deficiency is suspected. Routine population screening of healthy adults not recommended.
Endocrine Society 2011 (adult GH deficiency)
- →
Morning cortisol
Lab markerMorning serum cortisol is a first-line screen for adrenal insufficiency (low) or, via dexamethasone suppression, Cushing's (high), ordered for suspected disease, not routine longevity screening.
Endocrine Society 2016 · +1 more
- →
RBC magnesium
Lab markerNo body recommends population magnesium screening. Testing is reserved for symptoms, malabsorption, diuretic or PPI use, or refractory hypokalaemia/hypocalcaemia.
No screening guideline
- →
Zinc (RBC)
Lab markerNo routine population screening; assess in suspected deficiency (poor intake, malabsorption, high demand), interpreting any single biomarker alongside diet and clinical picture.
BOND zinc review 2016
- →
Faecal calprotectin
Lab markerRecommended to help distinguish IBD from IBS in adults with lower-GI symptoms where cancer is not suspected, to avoid unnecessary endoscopy.
NICE DG11 · +1 more
- →
DEXA scan
ImagingRisk-stratified screening from age 50, earlier if specific risk factors (steroid use, premature menopause, prior fragility fracture).
NOGG 2021 (UK)
- →
Coronary CT calcium score
ImagingAfter a score of zero, MESA data suggest a repeat scan is worth considering after about 3–7 years depending on age, sex and risk profile, sooner with diabetes.
MESA (Dzaye 2021)
- →
Colonoscopy
Imaging10-year interval after a high-quality normal colonoscopy in average-risk adults.
ESGE 2020
- →
Low-dose CT (lung)
ImagingSame eligibility plus consideration for additional risk factors (occupational exposure, family history).
NCCN 2024
- →
AAA ultrasound
ImagingOne-time ultrasound for men in the year they turn 65.
NHS AAA Screening Programme · +1 more
- →
Dermatological skin check
ImagingInsufficient evidence for routine population screening of asymptomatic adults.
USPSTF 2023 · +1 more
- →
Home sleep apnea test
ImagingAppropriate confirmatory study for uncomplicated suspected moderate-severe OSA. Not suitable for cases with significant comorbidity, suspected central apnea, or pediatric.
AASM 2017
- →
Polysomnography
ImagingIndicated when HSAT is inconclusive, when comorbidities or atypical presentations exist, for suspected central apnea, periodic limb movement disorder, parasomnias, or pediatric assessment.
AASM 2017
- →
Carotid intima-media thickness
ImagingRoutine CIMT measurement is not recommended for cardiovascular risk assessment in a first assessment (Class III). The earlier 2010 ACCF/AHA guideline had rated it Class IIa.
ACC/AHA 2013 · +2 more
- →
Grip strength
Functional testCentile charts cover ages 4 to 90, so a mid-life baseline can be compared with age- and sex-matched norms; no guideline sets a testing interval below age 60.
Normative data (Dodds 2014)
- →
6-minute walk test
Functional testStandardised protocol for clinical and research use. Periodic monitoring useful when tracking rehabilitation progress.
ATS / ERS 2014
- →
Push-up capacity
Functional testReasonable annual self-tracking from age 30. Cohort evidence is strongest in middle-aged adults.
ACSM 2022
- →
Comprehensive stool microbiome
Functional testNot recommended for routine clinical use or self-diagnosis. If used at all, treat as an exploratory snapshot; composition changes with diet within days.
Microbiome research literature
- →
Heart rate variability (HRV)
Wearable metricIn athlete studies, daily morning readings summarised as 7-day rolling averages are used; single values are noisy.
Athlete monitoring studies (Plews 2014) · +1 more
- →
VO₂max
Wearable metricCardiorespiratory fitness should be considered a clinical vital sign; reasonable to assess (by estimation or formal test) at routine preventive visits.
AHA 2016 · +1 more
- →
Resting heart rate
Wearable metricTrack as a daily/weekly metric; trends matter more than single readings.
AHA 2016
- →
Sleep efficiency
Wearable metricTrack over weekly rolling averages; identify patterns rather than fixating on single nights.
Common practice
- →
Blood pressure
Wearable metricAnnual screening for adults 40+; every 3–5 years for adults 18–39 at low risk. Home or ambulatory confirmation before diagnosing hypertension.
USPSTF 2021 · +3 more
- →
Waist circumference
Wearable metricUseful at any age; track monthly when working on body composition, otherwise annually.
WHO 2008 · +1 more
- →
Sleep regularity index
Wearable metricRead as a rolling weekly trend, not a single night; the value of regularity is in sustained consistency.
Sleep-health framing
- →
Sleep-onset latency
Wearable metricTrack latency alongside other symptoms over at least 2 weeks; insomnia is a clinical pattern over time, not one bad night.
European insomnia guideline 2023
- →
STOP-Bang
QuestionnaireQuestionnaires and prediction tools should not be used to diagnose OSA without a sleep study. Adults with symptoms or risk factors (habitual snoring, witnessed apnoeas, daytime sleepiness, obesity, treatment-resistant hypertension, atrial fibrillation) should have a comprehensive sleep evaluation.
AASM 2017 · +2 more
- →
Epworth Sleepiness Scale
QuestionnaireQuestionnaires such as the ESS can support a clinical assessment but should not be used to diagnose OSA without a sleep study.
AASM 2017
- →
PHQ-9
QuestionnaireRecommends screening for depression in all adults; instruments like PHQ-9 are the standard tool.
USPSTF 2023
- →
GAD-7
QuestionnaireRecommends screening for anxiety disorders in all adults aged 19–64.
USPSTF 2023
- →
MoCA
QuestionnaireEvidence is insufficient to assess screening for cognitive impairment in older adults without symptoms; tools like the MoCA are used when a patient, family member or clinician raises a concern.
USPSTF 2020
- →
PSQI
QuestionnaireUsed in clinical sleep evaluation and to track response to treatment such as CBT-I over weeks.
Common research / clinical practice
- →
AUDIT-C
QuestionnaireRecommends screening for unhealthy alcohol use in adults aged 18+ with brief intervention for those at risk. AUDIT-C is the most-used screening instrument.
USPSTF 2018
- →
UCLA Loneliness Scale (Version 3)
QuestionnaireUseful as a baseline and periodic re-measure during major life transitions (retirement, bereavement, relocation).
Common research / clinical practice
- →
Sleep apnea workup
Screening workflowQuestionnaires such as STOP-Bang and ESS should not be used to diagnose OSA without a sleep study. HSAT is acceptable for uncomplicated suspected moderate-to-severe OSA; PSG for ambiguous or comorbid cases.
AASM 2017 · +1 more
Your 40s
The decade when cardiovascular reference shifts from optional to standard.
- →
ApoB
Lab markerApoB is recommended for risk assessment, particularly in people with high triglycerides, diabetes, obesity or very low LDL-C.
ESC/EAS 2019 dyslipidaemia · +2 more
- →
hsCRP
Lab markerOptional addition to global risk assessment in intermediate-risk adults; repeat fasting if elevated to rule out transient cause.
AHA/CDC 2003 · +1 more
- →
HbA1c
Lab markerScreen for prediabetes/diabetes in adults 35–70 who are overweight or obese; every 3 years if normal.
USPSTF 2021 · +2 more
- →
Vitamin D (25-OH)
Lab markerRoutine testing not recommended in healthy adults, including those with darker skin or obesity; testing remains appropriate in conditions such as malabsorption or osteoporosis.
Endocrine Society 2024 · +1 more
- →
Ferritin
Lab markerTest in adults with unexplained fatigue, reduced exercise capacity, restless legs, hair loss, or menstrual blood loss.
BSH 2021 · +1 more
- →
Lipoprotein(a)
Lab markerMeasure at least once in every adult's lifetime; reasonable in young adulthood. Repeat testing usually not needed.
ESC 2019 dyslipidaemia · +1 more
- →
Homocysteine
Lab markerSometimes measured once as part of an extended cardiovascular workup; repeated if B12/folate are being corrected.
Expert review (Spence 2007), no screening guideline
- →
Fasting insulin
Lab markerNo guideline recommends routine fasting-insulin testing; assays are not standardised. A doctor may consider it alongside glucose tests when insulin resistance is suspected.
No screening guideline
- →
HOMA-IR
Lab markerUseful when investigating early insulin resistance; less helpful once diabetes is established.
Common practice
- →
Triglycerides
Lab markerPart of standard lipid screening from age 40 (or earlier with risk factors).
ESC 2019 dyslipidaemia
- →
Omega-3 Index
Lab markerUseful once to establish baseline; repeat 3–6 months after starting or stopping omega-3 supplementation.
Common practice
- →
eGFR
Lab markerAnnual creatinine + eGFR for adults with diabetes, hypertension, or known CKD.
KDIGO 2024 · +1 more
- →
Cystatin C
Lab markerUse cystatin C when creatinine-based eGFR is suspected to misclassify (extreme body composition, or borderline result).
KDIGO 2024
- →
TSH
Lab markerNo routine screening; test when symptoms or risk factors are present.
ATA 2014 · +1 more
- →
Free T4
Lab markerTest alongside TSH when TSH is abnormal, or when central thyroid disease is suspected.
ATA 2014
- →
Testosterone (total)
Lab markerMeasure in men with consistent symptoms (low libido, fatigue, depressed mood, reduced muscle mass). Repeat for confirmation before treating.
Endocrine Society 2018 (men) · +1 more
- →
LDL-C
Lab markerPart of routine cardiovascular risk assessment from age 40.
ESC 2021
- →
HDL-C
Lab markerPart of routine cardiovascular risk assessment from age 40.
ESC 2021
- →
Non-HDL-C
Lab markerReported alongside LDL-C in modern panels.
ESC 2021
- →
Fasting glucose
Lab markerScreen for prediabetes and type 2 diabetes in adults 35–70 with overweight or obesity; every 3 years if normal.
USPSTF 2021 · +1 more
- →
ALT
Lab markerEvaluate persistently elevated ALT regardless of magnitude; investigate metabolic, alcohol, viral, and drug causes.
AASLD 2017 (Kwo) · +1 more
- →
GGT
Lab markerHelpful when characterising hepatobiliary patterns alongside ALT, AST, ALP. Routine isolated screening not recommended.
AASLD 2017 (Kwo)
- →
Albumin
Lab markerReviewed at any routine blood draw. Trend over years carries more signal than any single value.
Standard panel inclusion
- →
PSA
Lab markerShared decision-making from age 50; from 45 with elevated risk (family history, African American men).
ACS 2024
- →
Vitamin B12
Lab markerTest in adults with unexplained anaemia, macrocytosis, neurological symptoms, glossitis, or risk factors (vegan/vegetarian diet, metformin or PPI use, autoimmune conditions, prior gastrointestinal surgery).
BCSH 2014 (Devalia) · +1 more
- →
Folate
Lab markerMeasure alongside B12 when investigating macrocytic anaemia, unexplained symptoms, or pre-pregnancy planning.
BCSH 2014
- →
Iron studies
Lab markerOrder alongside ferritin when symptoms suggest iron deficiency despite normal ferritin, or when ferritin is elevated and overload is being considered.
BSH 2021
- →
Haemoglobin & CBC
Lab markerReviewed at any routine blood draw. Trend matters more than single-point values.
Standard panel inclusion
- →
uACR
Lab markerAnnual for adults with diabetes, hypertension, cardiovascular disease, or family history of CKD.
KDIGO 2024 · +1 more
- →
IGF-1
Lab markerIndicated when GH excess (acromegaly) or deficiency is suspected. Routine population screening of healthy adults not recommended.
Endocrine Society 2011 (adult GH deficiency)
- →
Morning cortisol
Lab markerMorning serum cortisol is a first-line screen for adrenal insufficiency (low) or, via dexamethasone suppression, Cushing's (high), ordered for suspected disease, not routine longevity screening.
Endocrine Society 2016 · +1 more
- →
RBC magnesium
Lab markerNo body recommends population magnesium screening. Testing is reserved for symptoms, malabsorption, diuretic or PPI use, or refractory hypokalaemia/hypocalcaemia.
No screening guideline
- →
Zinc (RBC)
Lab markerNo routine population screening; assess in suspected deficiency (poor intake, malabsorption, high demand), interpreting any single biomarker alongside diet and clinical picture.
BOND zinc review 2016
- →
Faecal calprotectin
Lab markerRecommended to help distinguish IBD from IBS in adults with lower-GI symptoms where cancer is not suspected, to avoid unnecessary endoscopy.
NICE DG11 · +1 more
- →
DEXA scan
ImagingRisk-stratified screening from age 50, earlier if specific risk factors (steroid use, premature menopause, prior fragility fracture).
NOGG 2021 (UK)
- →
Coronary CT calcium score
ImagingClass IIa for adults aged 40–75 at borderline-to-intermediate 10-year ASCVD risk (5–20%); particularly useful when decision-making about statin therapy is uncertain.
ACC/AHA 2018 · +2 more
- →
Mammography
ImagingBiennial screening for women 40–74 at average risk.
USPSTF 2024
- →
Colonoscopy
Imaging10-year interval after a high-quality normal colonoscopy in average-risk adults.
ESGE 2020
- →
Low-dose CT (lung)
ImagingSame eligibility plus consideration for additional risk factors (occupational exposure, family history).
NCCN 2024
- →
AAA ultrasound
ImagingOne-time ultrasound for men in the year they turn 65.
NHS AAA Screening Programme · +1 more
- →
Dermatological skin check
ImagingInsufficient evidence for routine population screening of asymptomatic adults.
USPSTF 2023 · +2 more
- →
Home sleep apnea test
ImagingAppropriate confirmatory study for uncomplicated suspected moderate-severe OSA. Not suitable for cases with significant comorbidity, suspected central apnea, or pediatric.
AASM 2017
- →
Polysomnography
ImagingIndicated when HSAT is inconclusive, when comorbidities or atypical presentations exist, for suspected central apnea, periodic limb movement disorder, parasomnias, or pediatric assessment.
AASM 2017
- →
Carotid intima-media thickness
ImagingRoutine CIMT measurement is not recommended for cardiovascular risk assessment in a first assessment (Class III). The earlier 2010 ACCF/AHA guideline had rated it Class IIa.
ACC/AHA 2013 · +2 more
- →
Grip strength
Functional testCentile charts cover ages 4 to 90, so a mid-life baseline can be compared with age- and sex-matched norms; no guideline sets a testing interval below age 60.
Normative data (Dodds 2014)
- →
6-minute walk test
Functional testStandardised protocol for clinical and research use. Periodic monitoring useful when tracking rehabilitation progress.
ATS / ERS 2014
- →
Push-up capacity
Functional testReasonable annual self-tracking from age 30. Cohort evidence is strongest in middle-aged adults.
ACSM 2022
- →
Comprehensive stool microbiome
Functional testNot recommended for routine clinical use or self-diagnosis. If used at all, treat as an exploratory snapshot; composition changes with diet within days.
Microbiome research literature
- →
Heart rate variability (HRV)
Wearable metricIn athlete studies, daily morning readings summarised as 7-day rolling averages are used; single values are noisy.
Athlete monitoring studies (Plews 2014) · +1 more
- →
VO₂max
Wearable metricCardiorespiratory fitness should be considered a clinical vital sign; reasonable to assess (by estimation or formal test) at routine preventive visits.
AHA 2016 · +1 more
- →
Resting heart rate
Wearable metricTrack as a daily/weekly metric; trends matter more than single readings.
AHA 2016
- →
Sleep efficiency
Wearable metricTrack over weekly rolling averages; identify patterns rather than fixating on single nights.
Common practice
- →
Blood pressure
Wearable metricAnnual screening for adults 40+; every 3–5 years for adults 18–39 at low risk. Home or ambulatory confirmation before diagnosing hypertension.
USPSTF 2021 · +3 more
- →
Waist circumference
Wearable metricUseful at any age; track monthly when working on body composition, otherwise annually.
WHO 2008 · +1 more
- →
Sleep regularity index
Wearable metricRead as a rolling weekly trend, not a single night; the value of regularity is in sustained consistency.
Sleep-health framing
- →
Sleep-onset latency
Wearable metricTrack latency alongside other symptoms over at least 2 weeks; insomnia is a clinical pattern over time, not one bad night.
European insomnia guideline 2023
- →
STOP-Bang
QuestionnaireQuestionnaires and prediction tools should not be used to diagnose OSA without a sleep study. Adults with symptoms or risk factors (habitual snoring, witnessed apnoeas, daytime sleepiness, obesity, treatment-resistant hypertension, atrial fibrillation) should have a comprehensive sleep evaluation.
AASM 2017 · +2 more
- →
Epworth Sleepiness Scale
QuestionnaireQuestionnaires such as the ESS can support a clinical assessment but should not be used to diagnose OSA without a sleep study.
AASM 2017
- →
PHQ-9
QuestionnaireRecommends screening for depression in all adults; instruments like PHQ-9 are the standard tool.
USPSTF 2023
- →
GAD-7
QuestionnaireRecommends screening for anxiety disorders in all adults aged 19–64.
USPSTF 2023
- →
MoCA
QuestionnaireEvidence is insufficient to assess screening for cognitive impairment in older adults without symptoms; tools like the MoCA are used when a patient, family member or clinician raises a concern.
USPSTF 2020
- →
PSQI
QuestionnaireUsed in clinical sleep evaluation and to track response to treatment such as CBT-I over weeks.
Common research / clinical practice
- →
AUDIT-C
QuestionnaireRecommends screening for unhealthy alcohol use in adults aged 18+ with brief intervention for those at risk. AUDIT-C is the most-used screening instrument.
USPSTF 2018
- →
UCLA Loneliness Scale (Version 3)
QuestionnaireUseful as a baseline and periodic re-measure during major life transitions (retirement, bereavement, relocation).
Common research / clinical practice
- →
Sleep apnea workup
Screening workflowQuestionnaires such as STOP-Bang and ESS should not be used to diagnose OSA without a sleep study. HSAT is acceptable for uncomplicated suspected moderate-to-severe OSA; PSG for ambiguous or comorbid cases.
AASM 2017 · +1 more
Your 50s
Cancer-screening cadence widens. Bone health enters the conversation for women.
- →
ApoB
Lab markerApoB is recommended for risk assessment, particularly in people with high triglycerides, diabetes, obesity or very low LDL-C.
ESC/EAS 2019 dyslipidaemia · +2 more
- →
hsCRP
Lab markerOptional addition to global risk assessment in intermediate-risk adults; repeat fasting if elevated to rule out transient cause.
AHA/CDC 2003 · +1 more
- →
HbA1c
Lab markerScreen for prediabetes/diabetes in adults 35–70 who are overweight or obese; every 3 years if normal.
USPSTF 2021 · +2 more
- →
Vitamin D (25-OH)
Lab markerRoutine testing not recommended in healthy adults, including those with darker skin or obesity; testing remains appropriate in conditions such as malabsorption or osteoporosis.
Endocrine Society 2024 · +1 more
- →
Ferritin
Lab markerTest in adults with unexplained fatigue, reduced exercise capacity, restless legs, hair loss, or menstrual blood loss.
BSH 2021 · +1 more
- →
Lipoprotein(a)
Lab markerMeasure at least once in every adult's lifetime; reasonable in young adulthood. Repeat testing usually not needed.
ESC 2019 dyslipidaemia · +1 more
- →
Homocysteine
Lab markerSometimes measured once as part of an extended cardiovascular workup; repeated if B12/folate are being corrected.
Expert review (Spence 2007), no screening guideline
- →
Fasting insulin
Lab markerNo guideline recommends routine fasting-insulin testing; assays are not standardised. A doctor may consider it alongside glucose tests when insulin resistance is suspected.
No screening guideline
- →
HOMA-IR
Lab markerUseful when investigating early insulin resistance; less helpful once diabetes is established.
Common practice
- →
Triglycerides
Lab markerPart of standard lipid screening from age 40 (or earlier with risk factors).
ESC 2019 dyslipidaemia
- →
Omega-3 Index
Lab markerUseful once to establish baseline; repeat 3–6 months after starting or stopping omega-3 supplementation.
Common practice
- →
eGFR
Lab markerAnnual creatinine + eGFR for adults with diabetes, hypertension, or known CKD.
KDIGO 2024 · +1 more
- →
Cystatin C
Lab markerUse cystatin C when creatinine-based eGFR is suspected to misclassify (extreme body composition, or borderline result).
KDIGO 2024
- →
TSH
Lab markerNo routine screening; test when symptoms or risk factors are present.
ATA 2014 · +1 more
- →
Free T4
Lab markerTest alongside TSH when TSH is abnormal, or when central thyroid disease is suspected.
ATA 2014
- →
Testosterone (total)
Lab markerMeasure in men with consistent symptoms (low libido, fatigue, depressed mood, reduced muscle mass). Repeat for confirmation before treating.
Endocrine Society 2018 (men) · +1 more
- →
LDL-C
Lab markerPart of routine cardiovascular risk assessment from age 40.
ESC 2021
- →
HDL-C
Lab markerPart of routine cardiovascular risk assessment from age 40.
ESC 2021
- →
Non-HDL-C
Lab markerReported alongside LDL-C in modern panels.
ESC 2021
- →
Fasting glucose
Lab markerScreen for prediabetes and type 2 diabetes in adults 35–70 with overweight or obesity; every 3 years if normal.
USPSTF 2021 · +1 more
- →
ALT
Lab markerEvaluate persistently elevated ALT regardless of magnitude; investigate metabolic, alcohol, viral, and drug causes.
AASLD 2017 (Kwo) · +1 more
- →
GGT
Lab markerHelpful when characterising hepatobiliary patterns alongside ALT, AST, ALP. Routine isolated screening not recommended.
AASLD 2017 (Kwo)
- →
Albumin
Lab markerReviewed at any routine blood draw. Trend over years carries more signal than any single value.
Standard panel inclusion
- →
PSA
Lab markerRisk-adapted screening from age 50 (or 45 with family history / African ancestry). Multiparametric MRI before biopsy if PSA elevated.
EAU 2024 · +1 more
- →
Vitamin B12
Lab markerTest in adults with unexplained anaemia, macrocytosis, neurological symptoms, glossitis, or risk factors (vegan/vegetarian diet, metformin or PPI use, autoimmune conditions, prior gastrointestinal surgery).
BCSH 2014 (Devalia) · +1 more
- →
Folate
Lab markerMeasure alongside B12 when investigating macrocytic anaemia, unexplained symptoms, or pre-pregnancy planning.
BCSH 2014
- →
Iron studies
Lab markerOrder alongside ferritin when symptoms suggest iron deficiency despite normal ferritin, or when ferritin is elevated and overload is being considered.
BSH 2021
- →
Haemoglobin & CBC
Lab markerReviewed at any routine blood draw. Trend matters more than single-point values.
Standard panel inclusion
- →
uACR
Lab markerAnnual for adults with diabetes, hypertension, cardiovascular disease, or family history of CKD.
KDIGO 2024 · +1 more
- →
IGF-1
Lab markerIndicated when GH excess (acromegaly) or deficiency is suspected. Routine population screening of healthy adults not recommended.
Endocrine Society 2011 (adult GH deficiency)
- →
Morning cortisol
Lab markerMorning serum cortisol is a first-line screen for adrenal insufficiency (low) or, via dexamethasone suppression, Cushing's (high), ordered for suspected disease, not routine longevity screening.
Endocrine Society 2016 · +1 more
- →
RBC magnesium
Lab markerNo body recommends population magnesium screening. Testing is reserved for symptoms, malabsorption, diuretic or PPI use, or refractory hypokalaemia/hypocalcaemia.
No screening guideline
- →
Zinc (RBC)
Lab markerNo routine population screening; assess in suspected deficiency (poor intake, malabsorption, high demand), interpreting any single biomarker alongside diet and clinical picture.
BOND zinc review 2016
- →
Faecal calprotectin
Lab markerRecommended to help distinguish IBD from IBS in adults with lower-GI symptoms where cancer is not suspected, to avoid unnecessary endoscopy.
NICE DG11 · +1 more
- →
DEXA scan
ImagingRisk-stratified screening from age 50, earlier if specific risk factors (steroid use, premature menopause, prior fragility fracture).
NOGG 2021 (UK)
- →
Coronary CT calcium score
ImagingClass IIa for adults aged 40–75 at borderline-to-intermediate 10-year ASCVD risk (5–20%); particularly useful when decision-making about statin therapy is uncertain.
ACC/AHA 2018 · +2 more
- →
Mammography
ImagingBiennial screening for women 40–74 at average risk.
USPSTF 2024 · +2 more
- →
Colonoscopy
ImagingScreening for adults 45–75; choice of FIT (annually), sigmoidoscopy + FIT, or colonoscopy (every 10 years if normal).
USPSTF 2021 · +2 more
- →
Low-dose CT (lung)
ImagingAnnual LDCT for adults 50–80 with ≥20 pack-year smoking history who currently smoke or quit within the past 15 years.
USPSTF 2021 · +1 more
- →
AAA ultrasound
ImagingOne-time ultrasound for men in the year they turn 65.
NHS AAA Screening Programme · +1 more
- →
Dermatological skin check
ImagingInsufficient evidence for routine population screening of asymptomatic adults.
USPSTF 2023 · +2 more
- →
Home sleep apnea test
ImagingAppropriate confirmatory study for uncomplicated suspected moderate-severe OSA. Not suitable for cases with significant comorbidity, suspected central apnea, or pediatric.
AASM 2017
- →
Polysomnography
ImagingIndicated when HSAT is inconclusive, when comorbidities or atypical presentations exist, for suspected central apnea, periodic limb movement disorder, parasomnias, or pediatric assessment.
AASM 2017
- →
Carotid intima-media thickness
ImagingRoutine CIMT measurement is not recommended for cardiovascular risk assessment in a first assessment (Class III). The earlier 2010 ACCF/AHA guideline had rated it Class IIa.
ACC/AHA 2013 · +2 more
- →
Grip strength
Functional testCentile charts cover ages 4 to 90, so a mid-life baseline can be compared with age- and sex-matched norms; no guideline sets a testing interval below age 60.
Normative data (Dodds 2014)
- →
6-minute walk test
Functional testStandardised protocol for clinical and research use. Periodic monitoring useful when tracking rehabilitation progress.
ATS / ERS 2014
- →
Push-up capacity
Functional testReasonable annual self-tracking from age 30. Cohort evidence is strongest in middle-aged adults.
ACSM 2022
- →
Comprehensive stool microbiome
Functional testNot recommended for routine clinical use or self-diagnosis. If used at all, treat as an exploratory snapshot; composition changes with diet within days.
Microbiome research literature
- →
Heart rate variability (HRV)
Wearable metricIn athlete studies, daily morning readings summarised as 7-day rolling averages are used; single values are noisy.
Athlete monitoring studies (Plews 2014) · +1 more
- →
VO₂max
Wearable metricCardiorespiratory fitness should be considered a clinical vital sign; reasonable to assess (by estimation or formal test) at routine preventive visits.
AHA 2016 · +1 more
- →
Resting heart rate
Wearable metricTrack as a daily/weekly metric; trends matter more than single readings.
AHA 2016
- →
Sleep efficiency
Wearable metricTrack over weekly rolling averages; identify patterns rather than fixating on single nights.
Common practice
- →
Blood pressure
Wearable metricAnnual screening for adults 40+; every 3–5 years for adults 18–39 at low risk. Home or ambulatory confirmation before diagnosing hypertension.
USPSTF 2021 · +3 more
- →
Waist circumference
Wearable metricUseful at any age; track monthly when working on body composition, otherwise annually.
WHO 2008 · +1 more
- →
Sleep regularity index
Wearable metricRead as a rolling weekly trend, not a single night; the value of regularity is in sustained consistency.
Sleep-health framing
- →
Sleep-onset latency
Wearable metricTrack latency alongside other symptoms over at least 2 weeks; insomnia is a clinical pattern over time, not one bad night.
European insomnia guideline 2023
- →
STOP-Bang
QuestionnaireQuestionnaires and prediction tools should not be used to diagnose OSA without a sleep study. Adults with symptoms or risk factors (habitual snoring, witnessed apnoeas, daytime sleepiness, obesity, treatment-resistant hypertension, atrial fibrillation) should have a comprehensive sleep evaluation.
AASM 2017 · +2 more
- →
Epworth Sleepiness Scale
QuestionnaireQuestionnaires such as the ESS can support a clinical assessment but should not be used to diagnose OSA without a sleep study.
AASM 2017
- →
PHQ-9
QuestionnaireRecommends screening for depression in all adults; instruments like PHQ-9 are the standard tool.
USPSTF 2023
- →
GAD-7
QuestionnaireRecommends screening for anxiety disorders in all adults aged 19–64.
USPSTF 2023
- →
MoCA
QuestionnaireEvidence is insufficient to assess screening for cognitive impairment in older adults without symptoms; tools like the MoCA are used when a patient, family member or clinician raises a concern.
USPSTF 2020
- →
PSQI
QuestionnaireUsed in clinical sleep evaluation and to track response to treatment such as CBT-I over weeks.
Common research / clinical practice
- →
AUDIT-C
QuestionnaireRecommends screening for unhealthy alcohol use in adults aged 18+ with brief intervention for those at risk. AUDIT-C is the most-used screening instrument.
USPSTF 2018
- →
UCLA Loneliness Scale (Version 3)
QuestionnaireUseful as a baseline and periodic re-measure during major life transitions (retirement, bereavement, relocation).
Common research / clinical practice
- →
Sleep apnea workup
Screening workflowQuestionnaires such as STOP-Bang and ESS should not be used to diagnose OSA without a sleep study. HSAT is acceptable for uncomplicated suspected moderate-to-severe OSA; PSG for ambiguous or comorbid cases.
AASM 2017 · +1 more
Your 60s
Functional decline becomes measurable. Annual review of strength, cognition, and screening cadence.
- →
ApoB
Lab markerApoB is recommended for risk assessment, particularly in people with high triglycerides, diabetes, obesity or very low LDL-C.
ESC/EAS 2019 dyslipidaemia · +2 more
- →
hsCRP
Lab markerOptional addition to global risk assessment in intermediate-risk adults; repeat fasting if elevated to rule out transient cause.
AHA/CDC 2003 · +1 more
- →
HbA1c
Lab markerScreen for prediabetes/diabetes in adults 35–70 who are overweight or obese; every 3 years if normal.
USPSTF 2021 · +2 more
- →
Vitamin D (25-OH)
Lab markerRoutine testing not recommended in healthy adults, including those with darker skin or obesity; testing remains appropriate in conditions such as malabsorption or osteoporosis.
Endocrine Society 2024 · +1 more
- →
Ferritin
Lab markerTest in adults with unexplained fatigue, reduced exercise capacity, restless legs, hair loss, or menstrual blood loss.
BSH 2021 · +1 more
- →
Lipoprotein(a)
Lab markerMeasure at least once in every adult's lifetime; reasonable in young adulthood. Repeat testing usually not needed.
ESC 2019 dyslipidaemia · +1 more
- →
Homocysteine
Lab markerSometimes measured once as part of an extended cardiovascular workup; repeated if B12/folate are being corrected.
Expert review (Spence 2007), no screening guideline
- →
Fasting insulin
Lab markerNo guideline recommends routine fasting-insulin testing; assays are not standardised. A doctor may consider it alongside glucose tests when insulin resistance is suspected.
No screening guideline
- →
HOMA-IR
Lab markerUseful when investigating early insulin resistance; less helpful once diabetes is established.
Common practice
- →
Triglycerides
Lab markerPart of standard lipid screening from age 40 (or earlier with risk factors).
ESC 2019 dyslipidaemia
- →
Omega-3 Index
Lab markerUseful once to establish baseline; repeat 3–6 months after starting or stopping omega-3 supplementation.
Common practice
- →
eGFR
Lab markerAnnual creatinine + eGFR for adults with diabetes, hypertension, or known CKD.
KDIGO 2024 · +1 more
- →
Cystatin C
Lab markerUse cystatin C when creatinine-based eGFR is suspected to misclassify (extreme body composition, or borderline result).
KDIGO 2024
- →
TSH
Lab markerNo routine screening; test when symptoms or risk factors are present.
ATA 2014 · +1 more
- →
Free T4
Lab markerTest alongside TSH when TSH is abnormal, or when central thyroid disease is suspected.
ATA 2014
- →
Testosterone (total)
Lab markerMeasure in men with consistent symptoms (low libido, fatigue, depressed mood, reduced muscle mass). Repeat for confirmation before treating.
Endocrine Society 2018 (men) · +1 more
- →
LDL-C
Lab markerPart of routine cardiovascular risk assessment from age 40.
ESC 2021
- →
HDL-C
Lab markerPart of routine cardiovascular risk assessment from age 40.
ESC 2021
- →
Non-HDL-C
Lab markerReported alongside LDL-C in modern panels.
ESC 2021
- →
Fasting glucose
Lab markerScreen for prediabetes and type 2 diabetes in adults 35–70 with overweight or obesity; every 3 years if normal.
USPSTF 2021 · +1 more
- →
ALT
Lab markerEvaluate persistently elevated ALT regardless of magnitude; investigate metabolic, alcohol, viral, and drug causes.
AASLD 2017 (Kwo) · +1 more
- →
GGT
Lab markerHelpful when characterising hepatobiliary patterns alongside ALT, AST, ALP. Routine isolated screening not recommended.
AASLD 2017 (Kwo)
- →
Albumin
Lab markerReviewed at any routine blood draw. Trend over years carries more signal than any single value.
Standard panel inclusion
- →
PSA
Lab markerGrade C (individual decision) for men 55–69; Grade D (recommend against) for men 70+. Understanding the overdiagnosis trade-off is central to the decision.
USPSTF 2018 · +2 more
- →
Vitamin B12
Lab markerTest in adults with unexplained anaemia, macrocytosis, neurological symptoms, glossitis, or risk factors (vegan/vegetarian diet, metformin or PPI use, autoimmune conditions, prior gastrointestinal surgery).
BCSH 2014 (Devalia) · +1 more
- →
Folate
Lab markerMeasure alongside B12 when investigating macrocytic anaemia, unexplained symptoms, or pre-pregnancy planning.
BCSH 2014
- →
Iron studies
Lab markerOrder alongside ferritin when symptoms suggest iron deficiency despite normal ferritin, or when ferritin is elevated and overload is being considered.
BSH 2021
- →
Haemoglobin & CBC
Lab markerReviewed at any routine blood draw. Trend matters more than single-point values.
Standard panel inclusion
- →
uACR
Lab markerAnnual for adults with diabetes, hypertension, cardiovascular disease, or family history of CKD.
KDIGO 2024 · +1 more
- →
IGF-1
Lab markerIndicated when GH excess (acromegaly) or deficiency is suspected. Routine population screening of healthy adults not recommended.
Endocrine Society 2011 (adult GH deficiency)
- →
Morning cortisol
Lab markerMorning serum cortisol is a first-line screen for adrenal insufficiency (low) or, via dexamethasone suppression, Cushing's (high), ordered for suspected disease, not routine longevity screening.
Endocrine Society 2016 · +1 more
- →
RBC magnesium
Lab markerNo body recommends population magnesium screening. Testing is reserved for symptoms, malabsorption, diuretic or PPI use, or refractory hypokalaemia/hypocalcaemia.
No screening guideline
- →
Zinc (RBC)
Lab markerNo routine population screening; assess in suspected deficiency (poor intake, malabsorption, high demand), interpreting any single biomarker alongside diet and clinical picture.
BOND zinc review 2016
- →
Faecal calprotectin
Lab markerRecommended to help distinguish IBD from IBS in adults with lower-GI symptoms where cancer is not suspected, to avoid unnecessary endoscopy.
NICE DG11 · +1 more
- →
DEXA scan
ImagingRisk-stratified screening from age 50, earlier if specific risk factors (steroid use, premature menopause, prior fragility fracture).
NOGG 2021 (UK)
- →
Coronary CT calcium score
ImagingClass IIa for adults aged 40–75 at borderline-to-intermediate 10-year ASCVD risk (5–20%); particularly useful when decision-making about statin therapy is uncertain.
ACC/AHA 2018 · +2 more
- →
Mammography
ImagingBiennial screening for women 40–74 at average risk.
USPSTF 2024 · +2 more
- →
Colonoscopy
ImagingScreening for adults 45–75; choice of FIT (annually), sigmoidoscopy + FIT, or colonoscopy (every 10 years if normal).
USPSTF 2021 · +2 more
- →
Low-dose CT (lung)
ImagingAnnual LDCT for adults 50–80 with ≥20 pack-year smoking history who currently smoke or quit within the past 15 years.
USPSTF 2021 · +1 more
- →
AAA ultrasound
ImagingOne-time ultrasound for men in the year they turn 65.
NHS AAA Screening Programme · +1 more
- →
Dermatological skin check
ImagingInsufficient evidence for routine population screening of asymptomatic adults.
USPSTF 2023 · +2 more
- →
Home sleep apnea test
ImagingAppropriate confirmatory study for uncomplicated suspected moderate-severe OSA. Not suitable for cases with significant comorbidity, suspected central apnea, or pediatric.
AASM 2017
- →
Polysomnography
ImagingIndicated when HSAT is inconclusive, when comorbidities or atypical presentations exist, for suspected central apnea, periodic limb movement disorder, parasomnias, or pediatric assessment.
AASM 2017
- →
Carotid intima-media thickness
ImagingRoutine CIMT measurement is not recommended for cardiovascular risk assessment in a first assessment (Class III). The earlier 2010 ACCF/AHA guideline had rated it Class IIa.
ACC/AHA 2013 · +2 more
- →
Grip strength
Functional testTest annually in adults 60+; in younger adults, baseline value useful for tracking trajectory.
EWGSOP2 2019 · +1 more
- →
Sit-to-stand test
Functional testEmbedded in the Short Physical Performance Battery as a core test from age 60.
SPPB
- →
Single-leg balance
Functional testThe 10-second test is a useful single-point marker in adults 51+.
Araujo 2022
- →
6-minute walk test
Functional testStandardised protocol for clinical and research use. Periodic monitoring useful when tracking rehabilitation progress.
ATS / ERS 2014
- →
Push-up capacity
Functional testReasonable annual self-tracking from age 30. Cohort evidence is strongest in middle-aged adults.
ACSM 2022
- →
Comprehensive stool microbiome
Functional testNot recommended for routine clinical use or self-diagnosis. If used at all, treat as an exploratory snapshot; composition changes with diet within days.
Microbiome research literature
- →
Heart rate variability (HRV)
Wearable metricIn athlete studies, daily morning readings summarised as 7-day rolling averages are used; single values are noisy.
Athlete monitoring studies (Plews 2014) · +1 more
- →
VO₂max
Wearable metricCardiorespiratory fitness should be considered a clinical vital sign; reasonable to assess (by estimation or formal test) at routine preventive visits.
AHA 2016 · +1 more
- →
Resting heart rate
Wearable metricTrack as a daily/weekly metric; trends matter more than single readings.
AHA 2016
- →
Sleep efficiency
Wearable metricTrack over weekly rolling averages; identify patterns rather than fixating on single nights.
Common practice
- →
Blood pressure
Wearable metricAnnual screening for adults 40+; every 3–5 years for adults 18–39 at low risk. Home or ambulatory confirmation before diagnosing hypertension.
USPSTF 2021 · +3 more
- →
Waist circumference
Wearable metricUseful at any age; track monthly when working on body composition, otherwise annually.
WHO 2008 · +1 more
- →
Sleep regularity index
Wearable metricRead as a rolling weekly trend, not a single night; the value of regularity is in sustained consistency.
Sleep-health framing
- →
Sleep-onset latency
Wearable metricTrack latency alongside other symptoms over at least 2 weeks; insomnia is a clinical pattern over time, not one bad night.
European insomnia guideline 2023
- →
STOP-Bang
QuestionnaireQuestionnaires and prediction tools should not be used to diagnose OSA without a sleep study. Adults with symptoms or risk factors (habitual snoring, witnessed apnoeas, daytime sleepiness, obesity, treatment-resistant hypertension, atrial fibrillation) should have a comprehensive sleep evaluation.
AASM 2017 · +2 more
- →
Epworth Sleepiness Scale
QuestionnaireQuestionnaires such as the ESS can support a clinical assessment but should not be used to diagnose OSA without a sleep study.
AASM 2017
- →
PHQ-9
QuestionnaireRecommends screening for depression in all adults; instruments like PHQ-9 are the standard tool.
USPSTF 2023
- →
GAD-7
QuestionnaireRecommends screening for anxiety disorders in all adults aged 19–64.
USPSTF 2023
- →
MoCA
QuestionnaireEvidence is insufficient to assess screening for cognitive impairment in older adults without symptoms; tools like the MoCA are used when a patient, family member or clinician raises a concern.
USPSTF 2020
- →
PSQI
QuestionnaireUsed in clinical sleep evaluation and to track response to treatment such as CBT-I over weeks.
Common research / clinical practice
- →
AUDIT-C
QuestionnaireRecommends screening for unhealthy alcohol use in adults aged 18+ with brief intervention for those at risk. AUDIT-C is the most-used screening instrument.
USPSTF 2018
- →
UCLA Loneliness Scale (Version 3)
QuestionnaireUseful as a baseline and periodic re-measure during major life transitions (retirement, bereavement, relocation).
Common research / clinical practice
- →
Sleep apnea workup
Screening workflowQuestionnaires such as STOP-Bang and ESS should not be used to diagnose OSA without a sleep study. HSAT is acceptable for uncomplicated suspected moderate-to-severe OSA; PSG for ambiguous or comorbid cases.
AASM 2017 · +1 more
Your 70s+
Maintenance of independence is the through-line. Many screenings shift from finding new disease to avoiding losing function.
- →
ApoB
Lab markerApoB is recommended for risk assessment, particularly in people with high triglycerides, diabetes, obesity or very low LDL-C.
ESC/EAS 2019 dyslipidaemia · +2 more
- →
hsCRP
Lab markerOptional addition to global risk assessment in intermediate-risk adults; repeat fasting if elevated to rule out transient cause.
AHA/CDC 2003 · +1 more
- →
HbA1c
Lab markerScreen for prediabetes/diabetes in adults 35–70 who are overweight or obese; every 3 years if normal.
USPSTF 2021 · +2 more
- →
Vitamin D (25-OH)
Lab markerRoutine testing not recommended in healthy adults, including those with darker skin or obesity; testing remains appropriate in conditions such as malabsorption or osteoporosis.
Endocrine Society 2024 · +1 more
- →
Ferritin
Lab markerTest in adults with unexplained fatigue, reduced exercise capacity, restless legs, hair loss, or menstrual blood loss.
BSH 2021 · +1 more
- →
Lipoprotein(a)
Lab markerMeasure at least once in every adult's lifetime; reasonable in young adulthood. Repeat testing usually not needed.
ESC 2019 dyslipidaemia · +1 more
- →
Homocysteine
Lab markerSometimes measured once as part of an extended cardiovascular workup; repeated if B12/folate are being corrected.
Expert review (Spence 2007), no screening guideline
- →
Fasting insulin
Lab markerNo guideline recommends routine fasting-insulin testing; assays are not standardised. A doctor may consider it alongside glucose tests when insulin resistance is suspected.
No screening guideline
- →
HOMA-IR
Lab markerUseful when investigating early insulin resistance; less helpful once diabetes is established.
Common practice
- →
Triglycerides
Lab markerPart of standard lipid screening from age 40 (or earlier with risk factors).
ESC 2019 dyslipidaemia
- →
Omega-3 Index
Lab markerUseful once to establish baseline; repeat 3–6 months after starting or stopping omega-3 supplementation.
Common practice
- →
eGFR
Lab markerAnnual creatinine + eGFR for adults with diabetes, hypertension, or known CKD.
KDIGO 2024 · +1 more
- →
Cystatin C
Lab markerUse cystatin C when creatinine-based eGFR is suspected to misclassify (extreme body composition, or borderline result).
KDIGO 2024
- →
TSH
Lab markerNo routine screening; test when symptoms or risk factors are present.
ATA 2014 · +1 more
- →
Free T4
Lab markerTest alongside TSH when TSH is abnormal, or when central thyroid disease is suspected.
ATA 2014
- →
Testosterone (total)
Lab markerMeasure in men with consistent symptoms (low libido, fatigue, depressed mood, reduced muscle mass). Repeat for confirmation before treating.
Endocrine Society 2018 (men) · +1 more
- →
LDL-C
Lab markerPart of routine cardiovascular risk assessment from age 40.
ESC 2021
- →
HDL-C
Lab markerPart of routine cardiovascular risk assessment from age 40.
ESC 2021
- →
Non-HDL-C
Lab markerReported alongside LDL-C in modern panels.
ESC 2021
- →
Fasting glucose
Lab markerScreen for prediabetes and type 2 diabetes in adults 35–70 with overweight or obesity; every 3 years if normal.
USPSTF 2021 · +1 more
- →
ALT
Lab markerEvaluate persistently elevated ALT regardless of magnitude; investigate metabolic, alcohol, viral, and drug causes.
AASLD 2017 (Kwo) · +1 more
- →
GGT
Lab markerHelpful when characterising hepatobiliary patterns alongside ALT, AST, ALP. Routine isolated screening not recommended.
AASLD 2017 (Kwo)
- →
Albumin
Lab markerReviewed at any routine blood draw. Trend over years carries more signal than any single value.
Standard panel inclusion
- →
PSA
Lab markerRisk-adapted screening from age 50 (or 45 with family history / African ancestry). Multiparametric MRI before biopsy if PSA elevated.
EAU 2024 · +1 more
- →
Vitamin B12
Lab markerTest in adults with unexplained anaemia, macrocytosis, neurological symptoms, glossitis, or risk factors (vegan/vegetarian diet, metformin or PPI use, autoimmune conditions, prior gastrointestinal surgery).
BCSH 2014 (Devalia) · +1 more
- →
Folate
Lab markerMeasure alongside B12 when investigating macrocytic anaemia, unexplained symptoms, or pre-pregnancy planning.
BCSH 2014
- →
Iron studies
Lab markerOrder alongside ferritin when symptoms suggest iron deficiency despite normal ferritin, or when ferritin is elevated and overload is being considered.
BSH 2021
- →
Haemoglobin & CBC
Lab markerReviewed at any routine blood draw. Trend matters more than single-point values.
Standard panel inclusion
- →
uACR
Lab markerAnnual for adults with diabetes, hypertension, cardiovascular disease, or family history of CKD.
KDIGO 2024 · +1 more
- →
IGF-1
Lab markerIndicated when GH excess (acromegaly) or deficiency is suspected. Routine population screening of healthy adults not recommended.
Endocrine Society 2011 (adult GH deficiency)
- →
Morning cortisol
Lab markerMorning serum cortisol is a first-line screen for adrenal insufficiency (low) or, via dexamethasone suppression, Cushing's (high), ordered for suspected disease, not routine longevity screening.
Endocrine Society 2016 · +1 more
- →
RBC magnesium
Lab markerNo body recommends population magnesium screening. Testing is reserved for symptoms, malabsorption, diuretic or PPI use, or refractory hypokalaemia/hypocalcaemia.
No screening guideline
- →
Zinc (RBC)
Lab markerNo routine population screening; assess in suspected deficiency (poor intake, malabsorption, high demand), interpreting any single biomarker alongside diet and clinical picture.
BOND zinc review 2016
- →
Faecal calprotectin
Lab markerRecommended to help distinguish IBD from IBS in adults with lower-GI symptoms where cancer is not suspected, to avoid unnecessary endoscopy.
NICE DG11 · +1 more
- →
DEXA scan
ImagingScreen women aged 65+; younger postmenopausal women with elevated fracture risk per FRAX.
USPSTF 2025 · +2 more
- →
Coronary CT calcium score
ImagingClass IIa for adults aged 40–75 at borderline-to-intermediate 10-year ASCVD risk (5–20%); particularly useful when decision-making about statin therapy is uncertain.
ACC/AHA 2018 · +2 more
- →
Mammography
ImagingBiennial screening for women 40–74 at average risk.
USPSTF 2024 · +2 more
- →
Colonoscopy
ImagingScreening for adults 45–75; choice of FIT (annually), sigmoidoscopy + FIT, or colonoscopy (every 10 years if normal).
USPSTF 2021 · +2 more
- →
Low-dose CT (lung)
ImagingAnnual LDCT for adults 50–80 with ≥20 pack-year smoking history who currently smoke or quit within the past 15 years.
USPSTF 2021 · +1 more
- →
AAA ultrasound
ImagingOne-time screening for men 65–75 who have ever smoked.
USPSTF 2019 · +2 more
- →
Dermatological skin check
ImagingInsufficient evidence for routine population screening of asymptomatic adults.
USPSTF 2023 · +2 more
- →
Home sleep apnea test
ImagingAppropriate confirmatory study for uncomplicated suspected moderate-severe OSA. Not suitable for cases with significant comorbidity, suspected central apnea, or pediatric.
AASM 2017
- →
Polysomnography
ImagingIndicated when HSAT is inconclusive, when comorbidities or atypical presentations exist, for suspected central apnea, periodic limb movement disorder, parasomnias, or pediatric assessment.
AASM 2017
- →
Carotid intima-media thickness
ImagingRoutine CIMT measurement is not recommended for cardiovascular risk assessment in a first assessment (Class III). The earlier 2010 ACCF/AHA guideline had rated it Class IIa.
ACC/AHA 2013 · +2 more
- →
Grip strength
Functional testTest annually in adults 60+; in younger adults, baseline value useful for tracking trajectory.
EWGSOP2 2019 · +1 more
- →
Sit-to-stand test
Functional testAnnual screening in adults 65+, or sooner with concern about falls or strength.
STEADI (CDC) · +1 more
- →
Gait speed
Functional testAnnual assessment in adults 65+; included in the sarcopenia diagnostic pathway.
EWGSOP2 2019 · +1 more
- →
Single-leg balance
Functional testPart of the falls risk assessment in adults 65+.
STEADI (CDC) · +1 more
- →
6-minute walk test
Functional testStandardised protocol for clinical and research use. Periodic monitoring useful when tracking rehabilitation progress.
ATS / ERS 2014
- →
Push-up capacity
Functional testReasonable annual self-tracking from age 30. Cohort evidence is strongest in middle-aged adults.
ACSM 2022
- →
Comprehensive stool microbiome
Functional testNot recommended for routine clinical use or self-diagnosis. If used at all, treat as an exploratory snapshot; composition changes with diet within days.
Microbiome research literature
- →
Heart rate variability (HRV)
Wearable metricIn athlete studies, daily morning readings summarised as 7-day rolling averages are used; single values are noisy.
Athlete monitoring studies (Plews 2014) · +1 more
- →
VO₂max
Wearable metricCardiorespiratory fitness should be considered a clinical vital sign; reasonable to assess (by estimation or formal test) at routine preventive visits.
AHA 2016 · +1 more
- →
Resting heart rate
Wearable metricTrack as a daily/weekly metric; trends matter more than single readings.
AHA 2016
- →
Sleep efficiency
Wearable metricTrack over weekly rolling averages; identify patterns rather than fixating on single nights.
Common practice
- →
Blood pressure
Wearable metricAnnual screening for adults 40+; every 3–5 years for adults 18–39 at low risk. Home or ambulatory confirmation before diagnosing hypertension.
USPSTF 2021 · +3 more
- →
Waist circumference
Wearable metricUseful at any age; track monthly when working on body composition, otherwise annually.
WHO 2008 · +1 more
- →
Sleep regularity index
Wearable metricRead as a rolling weekly trend, not a single night; the value of regularity is in sustained consistency.
Sleep-health framing
- →
Sleep-onset latency
Wearable metricTrack latency alongside other symptoms over at least 2 weeks; insomnia is a clinical pattern over time, not one bad night.
European insomnia guideline 2023
- →
STOP-Bang
QuestionnaireQuestionnaires and prediction tools should not be used to diagnose OSA without a sleep study. Adults with symptoms or risk factors (habitual snoring, witnessed apnoeas, daytime sleepiness, obesity, treatment-resistant hypertension, atrial fibrillation) should have a comprehensive sleep evaluation.
AASM 2017 · +2 more
- →
Epworth Sleepiness Scale
QuestionnaireQuestionnaires such as the ESS can support a clinical assessment but should not be used to diagnose OSA without a sleep study.
AASM 2017
- →
PHQ-9
QuestionnaireRecommends screening for depression in all adults; instruments like PHQ-9 are the standard tool.
USPSTF 2023
- →
MoCA
QuestionnaireEvidence is insufficient to assess screening for cognitive impairment in older adults without symptoms; tools like the MoCA are used when a patient, family member or clinician raises a concern.
USPSTF 2020
- →
PSQI
QuestionnaireUsed in clinical sleep evaluation and to track response to treatment such as CBT-I over weeks.
Common research / clinical practice
- →
AUDIT-C
QuestionnaireRecommends screening for unhealthy alcohol use in adults aged 18+ with brief intervention for those at risk. AUDIT-C is the most-used screening instrument.
USPSTF 2018
- →
UCLA Loneliness Scale (Version 3)
QuestionnaireUseful as a baseline and periodic re-measure during major life transitions (retirement, bereavement, relocation).
Common research / clinical practice
- →
Sleep apnea workup
Screening workflowQuestionnaires such as STOP-Bang and ESS should not be used to diagnose OSA without a sleep study. HSAT is acceptable for uncomplicated suspected moderate-to-severe OSA; PSG for ambiguous or comorbid cases.
AASM 2017 · +1 more
